Assessment of insulin-degrading enzyme inhibitor for the treatment of corneal erosion in a rat model.

IF 2.4 3区医学 Q2 OPHTHALMOLOGY

Graefe’s Archive for Clinical and Experimental Ophthalmology Pub Date : 2025-04-01 Epub Date: 2024-12-23 DOI:10.1007/s00417-024-06717-1

Levy Issac, Dollberg Dolev, Bahar Irit, Dotan Assaf, Issac Levy

{"title":"Assessment of insulin-degrading enzyme inhibitor for the treatment of corneal erosion in a rat model.","authors":"Levy Issac, Dollberg Dolev, Bahar Irit, Dotan Assaf, Issac Levy","doi":"10.1007/s00417-024-06717-1","DOIUrl":null,"url":null,"abstract":"Background: Diabetes poses a risk to diabetic keratopathy in up to two-thirds of patients. Insulin-degrading enzyme (IDE) is a protease that can break down insulin and several growth factors and may impair wound healing. Increased IDE levels have been found in fluid from diabetic skin ulcers. This study sought to determine the effect of IDE inhibitor on corneal wound healing in a rat model.Methods: Thirty-four male Wistar rats were divided into two groups: no diabetes and streptozocin-induced diabetes. Six weeks later, a 4-mm central corneal erosion was created under anesthesia in the right eye of all rats. In each group, half the rats were treated with ADT21 drops (IDE inhibitor) and half with NaCl 0.9% (sham) drops, four times daily. Image J analysis was performed to evaluate the area of erosion and healing rate.Results: There was a trend for more rapid healing in rats treated with IDEI than NaCl drops, regardless of the diabetic condition. Comparison of erosion closure over time revealed that the wounds closed significantly more quickly in the non-diabetic rats treated with IDEI than in the non-diabetic rats treated with NaCl (p = 0.045), overall mean closure time 56.00 h, 95% CI [50.54, 61.46]. No such difference was seen in the diabetic group.Conclusions: To our knowledge, this is the first study to test ADT21 drops as a novel treatment for corneal wound repair. Our results suggest a potential benefit of IDE inhibitor for treating corneal injury.","PeriodicalId":12795,"journal":{"name":"Graefe’s Archive for Clinical and Experimental Ophthalmology","volume":" ","pages":"1015-1021"},"PeriodicalIF":2.4000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095391/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Graefe’s Archive for Clinical and Experimental Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00417-024-06717-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Diabetes poses a risk to diabetic keratopathy in up to two-thirds of patients. Insulin-degrading enzyme (IDE) is a protease that can break down insulin and several growth factors and may impair wound healing. Increased IDE levels have been found in fluid from diabetic skin ulcers. This study sought to determine the effect of IDE inhibitor on corneal wound healing in a rat model.

Methods: Thirty-four male Wistar rats were divided into two groups: no diabetes and streptozocin-induced diabetes. Six weeks later, a 4-mm central corneal erosion was created under anesthesia in the right eye of all rats. In each group, half the rats were treated with ADT21 drops (IDE inhibitor) and half with NaCl 0.9% (sham) drops, four times daily. Image J analysis was performed to evaluate the area of erosion and healing rate.

Results: There was a trend for more rapid healing in rats treated with IDEI than NaCl drops, regardless of the diabetic condition. Comparison of erosion closure over time revealed that the wounds closed significantly more quickly in the non-diabetic rats treated with IDEI than in the non-diabetic rats treated with NaCl (p = 0.045), overall mean closure time 56.00 h, 95% CI [50.54, 61.46]. No such difference was seen in the diabetic group.

Conclusions: To our knowledge, this is the first study to test ADT21 drops as a novel treatment for corneal wound repair. Our results suggest a potential benefit of IDE inhibitor for treating corneal injury.

查看原文本刊更多论文

胰岛素降解酶抑制剂治疗大鼠角膜糜烂模型的评估。

背景：糖尿病对高达三分之二的患者有糖尿病性角膜病变的风险。胰岛素降解酶（IDE）是一种蛋白酶，可以分解胰岛素和几种生长因子，并可能损害伤口愈合。在糖尿病性皮肤溃疡的液体中发现IDE水平升高。本研究旨在确定IDE抑制剂对大鼠角膜创面愈合的影响。方法：34只雄性Wistar大鼠分为非糖尿病组和链脲佐菌素诱导糖尿病组。6周后，所有大鼠右眼在麻醉下形成4 mm的角膜中央糜烂。在每组中，一半大鼠给予ADT21滴剂（IDE抑制剂），一半大鼠给予氯化钠0.9%（假）滴剂，每天4次。图像J分析评估糜烂面积和愈合率。结果：无论糖尿病情况如何，IDEI治疗的大鼠比NaCl滴药愈合更快。经时间比较，非糖尿病大鼠IDEI伤口愈合速度明显快于非糖尿病大鼠NaCl伤口愈合速度（p = 0.045），总体平均愈合时间56.00 h, 95% CI[50.54, 61.46]。在糖尿病组中没有发现这种差异。结论：据我们所知，这是第一个测试ADT21滴剂作为角膜伤口修复的新疗法的研究。我们的结果提示IDE抑制剂治疗角膜损伤的潜在益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Graefe’s Archive for Clinical and Experimental Ophthalmology 医学-眼科学

CiteScore

5.40

自引率

7.40%

发文量

398

审稿时长

3 months

期刊介绍： Graefe''s Archive for Clinical and Experimental Ophthalmology is a distinguished international journal that presents original clinical reports and clini-cally relevant experimental studies. Founded in 1854 by Albrecht von Graefe to serve as a source of useful clinical information and a stimulus for discussion, the journal has published articles by leading ophthalmologists and vision research scientists for more than a century. With peer review by an international Editorial Board and prompt English-language publication, Graefe''s Archive provides rapid dissemination of clinical and clinically related experimental information.